Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VADER: Sodium Valproate + Anti-EGFR Maintenance in RAS WT mCRC
NCT05694936Phase 2Active, not recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valproic acid in metastatic colorectal cancer (mCRC), sponsored by Australasian Gastro-Intestinal Trials Group. Started Jan 2023; status: active, not recruiting.
02
Drugs
valproic acid
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05694936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694936.